Literature DB >> 29081990

A model for optimizing delivery of targeted radionuclide therapies into resection cavity margins for the treatment of primary brain cancers.

Raghu Raghavan1, Roger W Howell2, Michael R Zalutsky3.   

Abstract

Radionuclides conjugated to molecules that bind specifically to cancer cells are of great interest as a means to increase the specificity of radiotherapy. Currently, the methods to disseminate these targeted radiotherapeutics have been either systemic delivery or by bolus injection into the tumor or tumor resection cavity. Herein we model a potentially more efficient method of delivery, namely pressure-driven fluid flow, called convection-enhanced delivery (CED), where a device infuses the molecules in solution (or suspension) directly into the tissue of interest. In particular, we focus on the setting of primary brain cancer after debulking surgery, where the tissue margins surrounding the surgical resection cavity are infiltrated with tumor cells and the most frequent sites of tumor recurrence. We develop the combination of fluid flow, chemical kinetics, and radiation dose models needed to examine such protocols. We focus on Auger electron-emitting radionuclides (e.g. 67Ga, 77Br, 111In, 125I, 123I, 193mPt, 195mPt) whose short range makes them ideal for targeted therapy in this setting of small foci of tumor spread within normal tissue. By solving these model equations, we confirm that a CED protocol is promising in allowing sufficient absorbed dose to destroy cancer cells with minimal absorbed dose to normal cells at clinically feasible activity levels. We also show that Auger emitters are ideal for this purpose while the longer range alpha particle emitters fail to meet criteria for effective therapy (as neither would energetic beta particle emitters). The model is used with simplified assumptions on the geometry and homogeneity of brain tissue to allow semi-analytic solutions to be displayed, and with the purpose of a first examination of this new delivery protocol proposed for radionuclide therapy. However, we emphasize that it is immediately extensible to personalized therapy treatment planning as we have previously shown for conventional CED, at the price of requiring a fully numerical computerized approach.

Entities:  

Keywords:  CED; MNT; advection-reaction; brain cancer; infiltrating tumor; radionuclide; targeted radiotherapy

Year:  2017        PMID: 29081990      PMCID: PMC5658137          DOI: 10.1088/2057-1976/aa6db9

Source DB:  PubMed          Journal:  Biomed Phys Eng Express        ISSN: 2057-1976


  41 in total

1.  Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by auger electrons.

Authors:  Jean-Pierre Pouget; Lore Santoro; Laure Raymond; Nicolas Chouin; Manuel Bardiès; Caroline Bascoul-Mollevi; Helena Huguet; David Azria; Pierre-Olivier Kotzki; Monique Pèlegrin; Eric Vivès; André Pèlegrin
Journal:  Radiat Res       Date:  2008-08       Impact factor: 2.841

2.  MIRD pamphlet No. 25: MIRDcell V2.0 software tool for dosimetric analysis of biologic response of multicellular populations.

Authors:  Behrooz Vaziri; Han Wu; Atam P Dhawan; Peicheng Du; Roger W Howell
Journal:  J Nucl Med       Date:  2014-07-10       Impact factor: 10.057

3.  High-flow microinfusion: tissue penetration and pharmacodynamics.

Authors:  P F Morrison; D W Laske; H Bobo; E H Oldfield; R L Dedrick
Journal:  Am J Physiol       Date:  1994-01

4.  Convection-enhanced delivery of macromolecules in the brain.

Authors:  R H Bobo; D W Laske; A Akbasak; P F Morrison; R L Dedrick; E H Oldfield
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

Review 5.  Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the "binding site barrier".

Authors:  J N Weinstein; W van Osdol
Journal:  Cancer Res       Date:  1992-05-01       Impact factor: 12.701

Review 6.  Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients.

Authors:  David A Reardon; Michael R Zalutsky; Darell D Bigner
Journal:  Expert Rev Anticancer Ther       Date:  2007-05       Impact factor: 4.512

7.  An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a "binding site barrier".

Authors:  W van Osdol; K Fujimori; J N Weinstein
Journal:  Cancer Res       Date:  1991-09-15       Impact factor: 12.701

8.  Extracellular volume fraction and diffusion characteristics during progressive ischemia and terminal anoxia in the spinal cord of the rat.

Authors:  E Syková; J Svoboda; J Polák; A Chvátal
Journal:  J Cereb Blood Flow Metab       Date:  1994-03       Impact factor: 6.200

Review 9.  Targeting the nucleus: an overview of Auger-electron radionuclide therapy.

Authors:  Bart Cornelissen; Katherine A Vallis
Journal:  Curr Drug Discov Technol       Date:  2010-12

10.  Localized Irradiation of Cell Membrane by Auger Electrons Is Cytotoxic Through Oxidative Stress-Mediated Nontargeted Effects.

Authors:  Salomé Paillas; Riad Ladjohounlou; Catherine Lozza; Alexandre Pichard; Vincent Boudousq; Marta Jarlier; Samuel Sevestre; Marion Le Blay; Emmanuel Deshayes; Jane Sosabowski; Thierry Chardès; Isabelle Navarro-Teulon; Robert J Mairs; Jean-Pierre Pouget
Journal:  Antioxid Redox Signal       Date:  2016-07-05       Impact factor: 8.401

View more
  3 in total

1.  Antitumor Activity of Auger Electron Emitter 111In Delivered by Modular Nanotransporter for Treatment of Bladder Cancer With EGFR Overexpression.

Authors:  Andrey A Rosenkranz; Tatiana A Slastnikova; Tatiana A Karmakova; Maria S Vorontsova; Natalia B Morozova; Vasiliy M Petriev; Alexey S Abrosimov; Yuri V Khramtsov; Tatiana N Lupanova; Alexey V Ulasov; Raisa I Yakubovskaya; Georgii P Georgiev; Alexander S Sobolev
Journal:  Front Pharmacol       Date:  2018-11-19       Impact factor: 5.810

Review 2.  Modular Nanotransporters for Nuclear-Targeted Delivery of Auger Electron Emitters.

Authors:  Alexander S Sobolev
Journal:  Front Pharmacol       Date:  2018-08-27       Impact factor: 5.810

3.  Soluble Cyanobacterial Carotenoprotein as a Robust Antioxidant Nanocarrier and Delivery Module.

Authors:  Eugene G Maksimov; Alexey V Zamaraev; Evgenia Yu Parshina; Yury B Slonimskiy; Tatiana A Slastnikova; Alibek A Abdrakhmanov; Pavel A Babaev; Svetlana S Efimova; Olga S Ostroumova; Alexey V Stepanov; Ekaterina A Slutskaya; Anastasia V Ryabova; Thomas Friedrich; Nikolai N Sluchanko
Journal:  Antioxidants (Basel)       Date:  2020-09-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.